Page 1,579«..1020..1,5781,5791,5801,581..1,5901,600..»

Engineering a Solution for Diabetes – Daily Nexus

Posted: May 4, 2017 at 3:41 pm

An award that could potentially help find a solution to diabetes has been given to an associate professor in the mechanical engineering department at UCSB. Sumita Pennathur received the Visionary Award from the American Diabetes Association, which includes $1.625 million over the course of five years to fund her research.

Pennathur is one of two researchers nationwide who received this award in 2017. The Visionary Award is given to established, experienced investigators with demonstrated success in a different field who want to bring their expertise to diabetes research for the first time.

Im totally out of the field of diabetes. I had nothing to do with it until my daughter was diagnosed, Pennathur said.

Pennathurs daughter was diagnosed with Type 1 diabetes in 2015 when she was four years old.

Type 1 diabetes is an autoimmune disease in which the pancreas produces little to no insulin, a hormone that helps regulate blood sugar. This happens when the bodys immune system attacks and destroys the insulin-producing cells known as beta cells. Without insulin, the body cannot allow sugar to enter the bodys cells to produce energy.

Currently, the causes of Type 1 diabetes are not known, and the most effective way of treating it is through insulin therapy. Although effective, the treatment includes constant blood glucose monitoring that involves pricking finger tips and finding a way to get insulin into the body.

The Pathways to Stop Diabetes Initiative is aimed at addressing the shortage of research talent in diabetes. The ADA believes that by supporting researchers like Pennathur, they can help generate new solutions to these critical problems. Kevin Son/Daily Nexus

My daughter has to take 10 [insulin] shots a day in her stomach, maybe five but sometimes 10, Pennathur said. She needs to do the shots by herself in her stomach. Shes six years old. Imagine being a little kid and having to do that all the time.

Her daughters diagnosis has inspired her to address the challenge of diabetes monitoring, or continuous glucose monitoring (CGM).

More than several hundred attempts have been made to develop a technique for CGM, but only a couple of them have received FDA approval. The CGM devices currently on the market, including subcutaneous needles that stay in the body for about a week, need to be calibrated twice daily and can give inaccurate readings.

Instead of a monitor that remains inside of the body, Pennathur and her research group have planned to develop a daily disposable patch.

We have to make it disposable because you dont want to stick stuff in your body. Its like a Band-Aid. Were making it like a Band-Aid, Pennathur said.

Although a small device, the patch combines engineering, chemistry and biology, which requires help from other departments.

On campus were doing a patch, so its like an array of needles so its not individually going in and out; its all at once. On the patch is a little hydrogel just think of it as a gooey gel and inside that gel is a bunch of chemicals that were working [on] with [Guillermo] Bazan of the chemistry department, Pennathur said. Hes building a chemical that can not only, if glucose is there, recognize it, but when it recognizes it, it changes its structure so that it fluoresces differently. Itll amplify the fluorescence a lot if the glucose is there.

As of now, Pennathur and her group have built the microneedles and have established how to make the necessary chemicals.

We actually just figured it out. The postdoc is named Bing Wang and hes in Bazans group. He has just figured out the path hes going to take to [make] the gel. Its a bunch of steps. You have to build the chemistry, make sure it works, proof of concept and so he figured out the steps and now we get to do all the steps. Were hoping itll get done in a year, Pennathur said.

Karen Scida, a postdoc who is a part of Pennathurs group is testing the patch and making sure it accurately measures glucose at different levels. Additionally, Scida is coming up with a way of incorporating a thin layer of insulin on the patch itself.

It could talk to the glucose monitor, so its just an artificial pancreas. In other words, you dont have to keep measuring. No finger pricks, its just a patch and you can eat whatever you want to eat, Pennathur said.

Pennathurs approach seems to be the most promising one, but interestingly enough, her background is not in chemistry or biology. She received her bachelors and masters degree in aerospace engineering at the Massachusetts Institute of Technology (MIT) and her Ph.D. in aerospace engineering at Stanford.

I feel really lucky because I got some of the best education you could possibly get in building these things, and now Im a professor on these things and I want to build a medical device, so the fact Im doing this is terrible serendipity, Pennathur said. I dont want to say serendipity because that has a good connotation. This is terrible what happened to my daughter but at the same time Im going to fix it. No one is going to stop me. My motivation knows absolutely no bounds because this is the most important thing in my life my daughter and Im going to save her life.

With a problem this big, Pennathur believes that a solution can be found in areas outside the typical research.

Its interesting because a lot of times, for these types of problems, you need to think outside the box. You need innovative solutions. You got to do stuff that nobody else knows about, and somebody coming from aerospace engineering, right? Who would know that that person could do research in diabetes, and thats because theres all these things I know, like I build microneedles. I know how to build microneedles, I can make them better than anyone. I can physically go in the clean room and make them myself. People who study diabetes cant make microneedles, Pennathur said.

It is the skills she developed as an engineer that could find help find a way to continuously monitor blood glucose levels.

Its those extra little things you learn that help you get somewhere in life. Again, I hate using the word serendipity, but Ive been trying to do this all my life. I didnt really have some problem to solve; I was just making my tools, and then my daughter got diagnosed and now I have my problem to solve, Pennathur said. Theres nothing else Im going to do but this, and I am so blessed to have the tools in my toolbox to actually try to help. Im going every way and any way to make this happen as quickly and efficiently as humanly possible.

Read the original post:
Engineering a Solution for Diabetes - Daily Nexus

Posted in Diabetes | Comments Off on Engineering a Solution for Diabetes – Daily Nexus

Diabetes’ prevalence can be managed with diet, exercise | Lifestyles … – Journal Gazette and Times-Courier

Posted: May 4, 2017 at 3:41 pm

May the fourth be with you ... Sorry, I just couldnt help myself. Happy (early) Cinco de Mayo and Kentucky Derby Day, too! I hope youve gotten your tickets and will be joining us at your LifeSpan Center this Friday or Saturday to celebrate with us. I guarantee we will offer you delicious food and beverages, some laughs, and a great time.

Before we have that good time, lets get serious for a few minutes. Nearly 29.1 million Americans and one fourth of adults over the age of 65 have diabetes, a serious disease in which blood sugar (glucose) levels are above normal. Most people with diabetes have type 2, which used to be called adult-onset diabetes. At one time, type 2 diabetes was more common in people over age 45, but now, even children have the disease.

Diabetes can lead to problems such as heart disease, stroke, vision loss, kidney disease, and nerve damage. One out of four people do not know they have diabetes. Many people dont find out they have diabetes until they are faced with problems such as blurry vision or heart trouble. That's why you need to know if you are at risk for diabetes. This is nothing to brush to the side and ignore, folks.

The importance of managing diabetes to prevent diabetes-related health problems such as heart attack, stroke, kidney disease, vision loss, and amputation is very real. More and more people are being diagnosed with it every day. Approximately one-half of older adults have prediabetes. Scary!

And to add to the drama, many older adults may not show classic symptoms of hyperglycemia (including, but not limited to confusion, dizziness, hunger, and sweating). The extra glucose in the blood accumulates in the kidneys until the kidneys see it as an impurity to be filtered out. Common symptoms are dehydration, dry eyes, dry mouth, confusion, incontinence, and diabetes complications, such as neuropathy or nephropathy.2.

Regardless of age, diabetes is often a life-long condition and requires careful treatment. Eating better, sticking to a healthy diet that is low in sugar (including sugar from fruit) and saturated fats is the first step. It may help to see a registered dietitian nutritionist (RDN) who is a diabetes educator to help you create a healthy meal plan. Medicare will cover the visits every year so you wouldnt have to pay out of pocket for the visit.

Aerobic exercise can help you control your glucose level, manage your weight, and stay strong. The American Diabetes Association recommends exercising 30 minutes each day, at least five days a week. You can split up the exercise into 10-minutes of activity three times a day. In addition, do strength training such as free weights, resistance bands, or yoga, at least two times per week. Strength training builds muscle and helps control glucose levels.

Monitoring your blood sugar levels and taking your prescribed medications correctly is also a must. Your health care team should look at all of your health issues, and help mold a plan that is individualized for you. You should see a certified diabetes educator (CDE) to learn about all the aspects of self-management that you will need to know in order to diminish your risks for the complications of diabetes.

Six month from now millions of Americans will observe National Diabetes Month. So many people suffer from this disease and it is observed every November to bring attention to diabetes and its impact on millions of Americans. It also serves as a reminder to people who may be struggling with the demands of managing diabetes that they are not alone.

Living with diabetes has its ups and downs, but healthy lifestyle choices can give you more control over them. And more control means fewer health problems down the road and a better quality of life now.

The Coles County Council on Aging offices are located at the LifeSpan Center, 11021 E. Co. Rd. 800N, Charleston. The telephone number is 217-639-5150 for the Coles County Council on Aging and LifeSpan Center. Come join us each weekday at noon for Lunch at LifeSpan.

Peace Meals, sponsored by Sarah Bush Lincoln Health Center, are served Monday through Friday at a suggested donation of $3.50. To register, reserve a lunch or learn more, call 217-348-1800.

See more here:
Diabetes' prevalence can be managed with diet, exercise | Lifestyles ... - Journal Gazette and Times-Courier

Posted in Diabetes | Comments Off on Diabetes’ prevalence can be managed with diet, exercise | Lifestyles … – Journal Gazette and Times-Courier

CDC reports diabetes is on the rise among children – News 5 Cleveland

Posted: May 4, 2017 at 3:41 pm

CLEVELAND - An alarming number of new cases of diabetes are being diagnosed among American kids. A CDC report revealed last month that Type 1 and Type 2 diabetes are both on the rise.

The findings have doctors raising concerns and making sure parents know the signs and symptoms of diabetes among their children.

She just wasnt acting right but it was nothing I had experienced with the other children, said Tiffany Barzacchini.

Barzacchinis 7-year-old daughter was just 1 year old when she was rushed to the ER with the tell-tale symptoms of diabetes.

She was just lethargic at times, craving water, and by the third day of this, her breathing became real intense, said Barzacchini.

Isola is the youngest of five. None of her older siblings have ever displayed symptoms of diabetes and genetically, theres no trace of the disease in either her moms or dads family history.

The CDC is reporting though that Isola is not alone. In a ten year study of kids from just a few months, to 19-years-old it was discovered each year, there was an increase of 1.8% of new Type 1 diabetes cases and an increase of 4.8% of new Type 2 cases.

Frankly, we dont know the cause, said Dr. Roy Kim, the Section Head of Pediatric Endocrinology at the Cleveland Clinic Children's Hospital.

Kim finds the surge in new diabetes cases alarming.

We know that individuals must have a certain genetic predisposition to be at risk for Type 1 Diabetes but there must be other environmental triggers and frankly we just havent figured out what those triggers are, he said.

An increase in Type 2 among kids can be linked to an increase in overall American childhood obesity. Type 2 is directly tied to weight gain, lack of exercise, and unhealthy eating habits. But whats more confusing is a rise in Type 1, a lifelong condition, with the root cause still unknown.

What goes underappreciated is how life changing the diagnosis is for those kids and what they have to go through, said Kim.

It doesnt ever go away, you dont ever get a break from it, it is literally 24/7 that you have to manage it, said Barzacchini.

For Isolas family, managing her disease is a full time job. Her blood is checked for insulin first thing in the morning when she wakes up, at every meal and after physical activity which must be limited.

Its the same story for millions of Americans. According to the American Diabetes Association, every 23 seconds in this country, theres a new diabetes diagnosis. Its estimated those patients will pay around $14,000 a year in medical expenses dealing with the disease.

Ultimately in her lifetime Im hoping they have a cure, said Barzacchini.

Symptoms parents should be on the lookout for include increased thirst and urination among their children, a feeling of constant exhaustion or hunger, sometimes weight loss and in its severe form, Type 1 can lead to vomiting, severe dehydration, and a coma-like state.

Continued here:
CDC reports diabetes is on the rise among children - News 5 Cleveland

Posted in Diabetes | Comments Off on CDC reports diabetes is on the rise among children – News 5 Cleveland

Poxel shares jump 40% after diabetes trial hits primary goal – FierceBiotech

Posted: May 4, 2017 at 3:41 pm

A phase 2b trial of Poxels Type 2 diabetes candidate imeglimin has met its primary endpoint. The data sent shares in Poxel soaring 40% and set the company up to push into a phase 3 trial before the end of the year.

Investigators in Japan enrolled 299 patients and randomized them to receive one of three doses of imeglimin or placebo. Participants received the treatment twice a day for 24 weeks. The primary endpoint looked at glycated hemoglobin A1c, a type of hemoglobin that shows the three-month average plasma glucose concentration. A secondary efficacy endpoint looked at levels of fasting plasma glucose.

All three doses of imeglimin outperformed placebo in terms of reducing levels of the hemoglobin. The response was dose dependent. Subjects who received the lowest, 500 mg dose experienced a reduction of 0.52%. Participants who took the highest, 1500 mg dose experienced a reduction of 1.00%. The declines are larger than those seen in earlier trials in the U.S. and Europe.

Dose dependency was also evident in the analysis of the secondary endpoint. Only the two higher doses1000 mg and 1500 mgmet that endpoint. Analysis of additional secondary endpoints is ongoing. Poxel said the safety profile was consistent with that seen in earlier trials. Those studies found the safety profile of imeglimin was comparable to placebo.

Buoyed by the data, Poxel plans to talk to regulators in Japan in the third quarter and kick off a phase 3 study in the fourth quarter. That would set Poxel up to generate pivotal data in a market that is central to its plans.

In Japan, we believe imeglimin may be a prime candidate for first-line treatment as monotherapy and as an add-on to other glucose lowering therapies for the treatment of patients with Type 2 diabetes, Poxel CEO Thomas Kuhn said in a statement. Japan represents the second largest single market for Type 2 diabetes and is expected to grow to approximately $6 billion (5.5 billion) in annual sales in 2020.

Kuhn has previously expressed a willingness for Poxel to run clinical trials of imeglimin in Japan without the support of a partner but bring someone on board to handle commercialization. Poxel raised 26.5 million last year to fund a phase 3 trial in Japan. That round came two months after Poxel floated the idea of a Nasdaq IPO, only to back away in the face of an unreceptive market.

The development strategy in Europe and the U.S. is different. Poxel has long expressed an interest in partnering the asset in those markets before taking it into phase 3.

Merck Serono spinout Poxel thinks imeglimin can claim a slice of the diabetes market by affecting the bioenergetics of mitochondria and, in doing so, preserve the function of beta cells.

Visit link:
Poxel shares jump 40% after diabetes trial hits primary goal - FierceBiotech

Posted in Diabetes | Comments Off on Poxel shares jump 40% after diabetes trial hits primary goal – FierceBiotech

Diabetes prevention and treatment cooking classes start May 18 – Estes Park Trail-Gazette

Posted: May 4, 2017 at 3:41 pm

Local instructor Chazz Glaze will cover important diabetes-nutrition topics during this course. (Courtesy photo)

The Physicians Committee for Responsible Medicine (PCRM), a nonprofit dedicated to promoting preventive medicine, is offering a cooking class designed to help local residents with type 2 diabetes avoid complications from the disease and reduce or eliminate the need for medications.

Food for Life: The Power of Food for Diabetes Nutrition and Cooking Class will be held Thursdays from May 18 to June 8 at Salud Family Health Center, 1950 Redtail Hawk Dr. There is a suggested donation of $10 to attend the classes.

The course teaches participants how food choices can prevent and treat type 2 diabetes and arms them with practical cooking skills for making healthy and delicious meals. People who have type 2 diabetes, or concerns about developing diabetes and their friends and family members will benefit from the class.

"Research shows type 2 diabetes can be controlled and even reversed with a healthy plant-based diet," said Susan Levin, M.S., R.D., the director of nutrition education for PCRM. "A vegan diet can help people with diabetes control blood sugar more effectively than the standard diabetes dietary regimen."

The class, designed by physicians, diabetes educators, registered dietitians and professional chefs, offers an easy-to-follow dietary approach based on scientific research. Population studies and clinical research show that a low-fat, plant-based diet is effective at improving blood glucose levels, promoting weight loss, reducing cholesterol and lowering the risk of diabetes and other chronic diseases.

Local instructor Chazz Glaze will cover important diabetes-nutrition topics and guide students through the preparation of tasty and easy-to-prepare recipes. Participants will watch a 30-minute DVD featuring Neal Barnard, M.D., speaking on the role of meal planning, as well as inspiring interviews with people who reversed their diabetes with a vegan diet. They will also enjoy food samples of the recipes prepared in class.

The class details are as follows:

Thursday, May 18, 5:30 to 7:30 p.m. How Foods Fight Diabetes

Thursday, May 25, 5:30 to 7:30 p.m. The Power of Your Plate (and Grocery Cart)

Thursday, June 1, 5:30 to 7:30 p.m. Understanding Type 2 Diabetes and Recognizing and Treating Low Blood Sugar

Thursday, June 8, 5:30 to 7:30 p.m. Designing a Diet for Maximum Weight Control

Students will leave the class with delicious recipes, information on how to switch to a vegan diet and additional diabetes resources, including information on online webcasts and group support. Participants are strongly encouraged to work with their health care team to safely make dietary changes.

For more information about the Food for Life Diabetes Nutrition and Cooking Class program or to register for the classes, email Glaze at aveganwithaltitude@gmail.com or call (970) 235-1586.

Read the original here:
Diabetes prevention and treatment cooking classes start May 18 - Estes Park Trail-Gazette

Posted in Diabetes | Comments Off on Diabetes prevention and treatment cooking classes start May 18 – Estes Park Trail-Gazette

Puma Biotechnology (PBYI) Q1 Earnings: Stock to Disappoint? – Zacks.com

Posted: May 3, 2017 at 8:45 pm

Puma Biotechnology, Inc. (PBYI - Free Report) is expected to report first-quarter 2017 results later this month. The companys earnings track record is disappointing as it missed estimates in three of the trailing four quarters and met expectations in one. The company had an average negative surprise of 3.23% in the last four quarters.

Pumas shares have outperformed the Zacks classified Medical-Biomedical and Genetics industry, year to date. Shares of the company gained 27.2% so far this year, while the industry recorded an increase of 5.5%.

In the last reported quarter, Puma posted a negative surprise of 0.99%. Lets see how things are shaping up for this announcement.

Factors at Play

Being a development-stage company, Puma Biotech does not have any approved product in its portfolio. Thus, investor focus should remain on updates pertaining to the development of neratinib, its lead pipeline candidate.

The candidate is currently under review in both the U.S. and the EU for the extended adjuvant treatment of HER2-positive early-stage breast cancer in patients who have previously been treated with Herceptin-based adjuvant therapy.

Moreover, several phase II combination studies on neratinib for the treatment of breast cancer are currently underway.

In Apr 2017, Puma presented encouraging additional data from breast cancer studies at the San American Association for Cancer Research Annual (AACR) on neratinib. These include interim data from a phase II study in patients with HER2-positive early stage breast cancer who had completed trastuzumab-based adjuvant therapy; interim phase I/II data from the NSABP FB-10 trial of neratinib plus Kadcyla (T-DM1) in HER2-positive MBC; and phase II data from SUMMIT study in HER2-negative breast cancer patients with HER2 mutations.

Puma anticipates more data updates in the second quarter. These include additional data from the phase III study on neratinib in third-line HER2-positive metastatic breast cancer patients and data from a phase II study on neratinib in HER2-positive metastatic breast cancer patients with brain metastases.

Earnings Whispers

Our proven model does not conclusively show that Puma Biotech is likely to beat estimates this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here as you will see below.

Zacks ESP:TheEarnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is pegged at 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate stand at a loss of $2.08. You can uncover the best stocks to buy or sell before theyre reported with our Earnings ESP Filter.

Zacks Rank:Puma Biotechs carries a Zacks Rank #4 (Sell). As it is that we caution against stocks with a Zacks Rank #4 or 5 (Strong Sell) going into the earnings announcement, especially when the company is seeing negative estimate revisions.

Other Stocks That Warrant a Look

Here are some health care stocks that you may want to consider as our model shows that these have the right combination of elements to post an earnings beat this quarter.

Conatus Pharmaceuticals Inc. (CNAT - Free Report) is scheduled to release results on May 4. The company has an Earnings ESP of +57.14% and a Zacks Rank #3. You can seethe complete list of todays Zacks #1 Rank stocks here.

ImmunoGen, Inc. (IMGN - Free Report) is scheduled to release results on May 5. The company has an Earnings ESP of +8.33% and a Zacks Rank #3.

FIBROGEN INC (FGEN - Free Report) is scheduled to release results on May 8. The company has an Earnings ESP of +23.81% and a Zacks Rank #3.

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>

Excerpt from:
Puma Biotechnology (PBYI) Q1 Earnings: Stock to Disappoint? - Zacks.com

Posted in Biotechnology | Comments Off on Puma Biotechnology (PBYI) Q1 Earnings: Stock to Disappoint? – Zacks.com

Northeast Financial Consultants Inc Sells 650 Shares of iShares NASDAQ Biotechnology Index (IBB) – The Cerbat Gem

Posted: May 3, 2017 at 8:45 pm


BBNS
Northeast Financial Consultants Inc Sells 650 Shares of iShares NASDAQ Biotechnology Index (IBB)
The Cerbat Gem
iShares NASDAQ Biotechnology Index logo Northeast Financial Consultants Inc cut its stake in shares of iShares NASDAQ Biotechnology Index (NASDAQ:IBB) by 48.1% during the first quarter, according to its most recent disclosure with the Securities and ...
iShares NASDAQ Biotechnology Index (IBB) Shares Bought by Beaumont Financial Partners LLCTranscript Daily
iShares NASDAQ Biotechnology Index (IBB) Stake Maintained by Barrett Asset Management LLCSports Perspectives
Stock Traders Buy Large Volume of iShares NASDAQ Biotechnology Index Call Options (IBB)Markets Daily
BBNS -Petro Global News 24 -Barron's
all 22 news articles »

Visit link:
Northeast Financial Consultants Inc Sells 650 Shares of iShares NASDAQ Biotechnology Index (IBB) - The Cerbat Gem

Posted in Biotechnology | Comments Off on Northeast Financial Consultants Inc Sells 650 Shares of iShares NASDAQ Biotechnology Index (IBB) – The Cerbat Gem

SQI Diagnostics to Exhibit at the National Biotechnology Conference – Markets Insider

Posted: May 3, 2017 at 8:45 pm

TORONTO, May 1, 2017 /CNW/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQX: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, will be exhibiting at the American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference in San Diego, California.

"We are pleased to be a contributor to this very prestigious conference," said Andrew Morris, CEO of SQI Diagnostics. "This event brings together the world's leading experts and representatives from all sectors of pharma and biotechnology drug development and gives us the opportunity to share our novel multiplexing applications in drug development testing. Over the past year, we have made significant progress in our work with our pharma and biotech customers and believeour unique productswill prove to be beneficial to our customers who are large, global pharmaceutical companies.

The conference will run from May 1-3, 2017. Please stop by and visit us at booth 316.

About SQI Diagnostics

SQI Diagnostics is a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics. The Company's proprietary microarray tests and fully-automated systems are designed to simplify protein and antibody testing workflow, increase throughput, reduce costs and provide excellent data quality. For more information, please visit http://www.sqidiagnostics.com.

Contacts:

Sales and Marketing Contact: Russ Peloquin Vice President, Global Commercial Operations 913.484.9022 rel="nofollow">rpeloquin@sqidiagnostics.com

Investor Relations Contact: Andrew Morris Chief Executive Officer 416.674.9500 ext. 229 rel="nofollow">amorris@sqidiagnostics.com

Forward-looking Information

This news release contains certain forward-looking statements, including, without limitation, statements containing the words "will", "may", "expects", "intends", "anticipates" and other similar expressions which constitute "forward-looking information" within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. The forward-looking statements in this news release include without limitation, statements with respect to the Private Placement and the use of proceeds of the Private Placement. These forward-looking statements involve risks and uncertainties including, but not limited to risks related to the failure to obtain necessary regulatory and stock exchange approvals, general economic and market segment conditions, and international risk and currency exchange risks, agreements and future agreements to sell our products, the success of our Diagnostic Tools and Services business and our intent to build near-term revenue streams from this business, the successful regulatory filing and receipt of regulatory approvals for our later stage quantitative diagnostic kits, the acceleration of our revenue ramp, general economic and market segment conditions, competitor activity, technology changes and regulatory approvals. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company's ongoing filings with the securities regulatory authorities, which filings can be found at http://www.sedar.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable laws.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the U.S. Securities Act or any state securities laws and may not be offered or sold within the United States or to U.S. persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE SQI Diagnostics Inc.

Visit link:
SQI Diagnostics to Exhibit at the National Biotechnology Conference - Markets Insider

Posted in Biotechnology | Comments Off on SQI Diagnostics to Exhibit at the National Biotechnology Conference – Markets Insider

ChineseInvestors.com, Inc. Appoints Summer Yun as CEO of CBD Biotechnology Co., Ltd., Wholly-owned Foreign Entity – Markets Insider

Posted: May 3, 2017 at 8:45 pm

SAN GABRIEL, California, May 2, 2017 /PRNewswire/ --

ChineseInvestors.com, Inc. (OTCQB: CIIX) ("CIIX" or the "Company"), the premier financial information website for Chinese-speaking investors, today announces that it has appointed Summer (XiangYang) Yun as Chief Executive Officer (CEO) of its wholly-owned foreign entity, CBD Biotechnology Co., Ltd. ("XiBiDi Biotech"). XiBiDi Biotech's primary focus is online, retail and direct sales of hemp-based health products in China. Yun's initial focus will be the launch of 'CBD Magic Hemp Series' cosmetics line. He will also spearhead the Company's plan to import natural dietary supplements created using advanced extracting and purifying technologies into China. Yun is a marketing and branding executive with over 25 years of experience. Yun will report directly to CIIX's CEO Warren Wang.

"I am honored to be named as CEO of CBD Biotech," says Yun. "For over 5,000 years, hemp has been cultivated and used in over 25,000 products worldwide. CIIX has a unique opportunity to become one of the first companies to offer CBD-based skin care products in China online and through established retail and direct selling channels. Through the introduction of Magic CBD Series cosmetics to China, I hope to educate consumers regarding hemp's many benefits."

The CBD Magic Hemp Series line will include cleansers, moisturizing lotions and anti-aging products created using supercritical CO2 extraction technology. CBD Biotech also plans to launch a series of oral spray vitamins and supplements that can be used for relaxation, pain relief and sleep, among others things. Yun will oversee marketing and sales of these products in China, and utilizing his branding and marketing expertise, he will work to grow the CBD Biotech brand.

"I believe Yun is the perfect candidate to oversee CBD Biotech's operations. I am confident in his ability to introduce this revolutionary CBD-based skin care line to China and create and generate substantial revenue for CIIX," says Wang.

Yun served as a marketing executive for the cosmetics branch company of TianJing Department Store to introduce both Procter & Gamble and Ponds to the Chinese market. As a brand agent, Yun experienced how Procter & Gamble cooperated with GuangZhou Soap Factory to enter the Chinese market, where he introduced the Head & Shoulders and Olay brands to the Chinese market. In 1996, Yun founded Sino-US Trade Development Co., Ltd. in TianJing Development Zone, and at the same time introduced the French L'anfu Cosmetics brand and Shanghai L'anfu Cosmetics brand to the Chinese market. Over the past 28 years, Yun has served as Chinese brand agent to many major skin and health care brands.

About ChineseInvestors.com (OTCQB: CIIX)

Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail and online sales of hemp-based products and other health related products

For more information visit ChineseInvestors.com

Subscribe and watch our video commentaries: https://www.youtube.com/user/Chinesefncom

Follow us on Twitter for real-time Company updates: https://twitter.com/ChineseFNEnglsh

Like us on Facebook to receive live feeds:https://www.facebook.com/Chinesefncom

Add us on WeChat: Chinesefn or download iPhone iOS App: Chinesefn.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Contact: ChineseInvestors.com, Inc. 227 W. Valley Blvd, #208 A San Gabriel, CA 91776

Investor Relations: Alan Klitenic +1-214-636-2548

Corporate Communications: NetworkNewsWire (NNW) New York, New York http://www.NetworkNewsWire.com +1-212-418-1217 Office rel="nofollow">Editor@NetworkNewsWire.com

SOURCE ChineseInvestors.com, Inc.

Original post:
ChineseInvestors.com, Inc. Appoints Summer Yun as CEO of CBD Biotechnology Co., Ltd., Wholly-owned Foreign Entity - Markets Insider

Posted in Biotechnology | Comments Off on ChineseInvestors.com, Inc. Appoints Summer Yun as CEO of CBD Biotechnology Co., Ltd., Wholly-owned Foreign Entity – Markets Insider

Beta Cell Growth Finding May Lead to Improved Therapies for Diabetics – Genetic Engineering & Biotechnology News (press release)

Posted: May 3, 2017 at 8:45 pm

Scientists at theUniversity of California San Diego School of Medicine usedsingle-cell RNA sequencing to map out pathways that regulate cell growth that could be exploited to trick them to regenerate.

Pancreatic cells help maintain normal blood glucose levels by producing insulin, the master regulator of energy (glucose). Impairment and the loss of cells interrupts insulin production, leading to types 1 and 2 diabetes.The team's study ("Pseudotemporal Ordering of Single Cells Reveals Metabolic Control of Postnatal Cell Proliferation") is published in Cell Metabolism.

"If we can find a drug that makes cells grow, it could improve blood sugar levels in people with diabetes," said Maike Sander, M.D., professor in the Department of Pediatrics and Cellular and Molecular Medicine at UC San Diego School of Medicine. "These people often have residual cells, but not enough to maintain normal blood glucose levels."

The body generates cells in utero and they continue to regenerate after birth. But as people age, cell regeneration diminishes. The predominant way to grow new cells is through cell division; but cells capable of dividing are rare, compromising less than 1% of all cells. Scientists have been investigating molecular pathways that govern cell growth in hopes of finding new therapies that would help people regain blood glucose control after the onset of diabetes.

In their work, Dr. Sander's team identified the pathways that are active when cells divide, providing insight into possible drug targets. The investigators were able to profile molecular features and metabolic activity of individual cells to determine how dividing cells differ from nondividing cells.

"No one has been able to do this analysis because the 1% or less of cells that are dividing are masked by the 99% percent of cells that are not dividing," said Dr. Sander. "This in-depth characterization of individual cells in different proliferative states was enabled by newer technology. It provides a better picture of what sends cells into cell division and clues we can use to try to develop drugs to stimulate certain pathways."

Whether stimulating cells to grow will result in therapeutic interventions for diabetes is still to be seen, but this new information opens the door to find out, she added.

More here:
Beta Cell Growth Finding May Lead to Improved Therapies for Diabetics - Genetic Engineering & Biotechnology News (press release)

Posted in Cell Medicine | Comments Off on Beta Cell Growth Finding May Lead to Improved Therapies for Diabetics – Genetic Engineering & Biotechnology News (press release)

Page 1,579«..1020..1,5781,5791,5801,581..1,5901,600..»